What the 10-year evidence actually shows

At ten years, mosaicplasty produces better clinical outcomes than microfracture for focal knee cartilage defects. That is the most direct conclusion available from the published evidence, and it is worth stating plainly before unpacking the caveats.

The clearest head-to-head data comes from the Gudas et al. prospective randomised controlled trial, which compared the two techniques in young athletes and tracked outcomes to ten years — among the longest direct comparisons ever completed for these procedures. Mosaicplasty held a meaningful advantage on clinical scores at that endpoint. The 2021 Cartilage textbook corroborates this pattern explicitly, noting that mosaicplasty has been shown to produce higher clinical scores than microfracture in long-term follow-up.

In the short term, the picture is more evenly matched: both procedures yield genuine improvements, and for lesions under 2–4 cm² either can be a reasonable choice. The divergence tends to emerge progressively from around five years onwards, becoming more consistent by the ten-year mark.

The honest qualification is that this verdict rests primarily on cohort studies, meta-analyses, and a small number of RCTs rather than a large body of identical trials. The conclusion is well-supported, but individual patient factors — defect size, age, activity demands — still carry significant weight in any clinical decision.

What each procedure does to knee cartilage

The two procedures take fundamentally different approaches to the same problem: a patch of missing or damaged articular cartilage on the knee's joint surface.

Microfracture works by making small perforations through the hard subchondral bone beneath the defect. Blood and marrow cells flood in, forming a clot that gradually matures into fibrocartilage — a repair tissue dominated by type I collagen, the same fibrous protein found in scar tissue. It covers the defect and can relieve symptoms, but it is structurally less stiff and less resistant to repeated loading than native cartilage.

Mosaicplasty transplants cylindrical plugs of osteochondral tissue — bone plus the cartilage above it — taken from a lower-load area of the same knee, typically the peripheral trochlea or intercondylar notch, and press-fitted into the defect. Those plugs carry native hyaline cartilage, built around type II collagen, with the same mechanical architecture as the original joint surface. The bone component of each plug integrates directly with the host bone beneath, anchoring the graft structurally from day one.

The distinction matters because articular cartilage must withstand millions of loading cycles each year. Fibrocartilage, being a biological compromise rather than a true structural replacement, may gradually break down under that sustained demand — a deterioration documented by Mithoefer et al. (2009) in long-term follow-up of microfracture cohorts. This tissue-quality gap is the most plausible biological explanation for why the clinical advantage of mosaicplasty tends to widen over a decade, independent of differences in surgical technique.

Why microfracture results tend to decline after five years

Fibrocartilage, already less resilient under cyclic joint loading than the native tissue it replaced, has no structural reserve when the bone plate beneath it becomes irregular or cystic. That is what the complication data from long-term microfracture follow-up shows is happening in a substantial proportion of knees.

The perforations created during microfracture can trigger a secondary centre of ossification within the repair site. Intralesional osteophytes — bony outgrowths that deform the base of the defect — were documented in 54% of patients at six months post-operatively and in up to 70% by twelve months. Separately, subchondral bone cysts develop in up to 33% of patients, creating voids beneath the fibrocartilage surface. Both changes deform the mechanical foundation on which the repair tissue depends, progressively destabilising it from below.

Long-term cohort data supports the clinical consequence. Mithoefer et al. (2009) documented a pattern of initial functional improvement followed by measurable deterioration in microfracture outcomes over time, and Steadman et al.'s series — tracking patients to an average of eleven years — showed a similar trajectory. The subchondral disruption described above provides the structural explanation for what those outcome curves reflect.

Mosaicplasty sidesteps this failure pathway because each transplanted plug brings its own intact subchondral bone plate. The bony base integrates with host bone directly, leaving the overlying hyaline cartilage mechanically supported in the same way it was at the donor site.

Which procedure suits which patient

Defect size is the primary variable surgeons use to decide between these two techniques, but it is rarely the only one.

For focal lesions under 2–4 cm², both microfracture and mosaicplasty are clinically reasonable choices. Within that range, the decision shifts to patient profile: younger, more active patients — particularly those returning to sport — tend to be offered mosaicplasty, given the long-term outcome advantage the evidence supports. Microfracture remains a practical option where surgical access is straightforward and the patient's activity demands are lower, or where surgeon experience favours it.

The strongest head-to-head data at ten years comes from the Gudas et al. prospective RCT, which enrolled young athletes. That population context matters: how well those results translate to older or less active patients remains uncertain, and surgeons will typically weigh individual factors rather than applying the RCT findings as a universal rule.

Mosaicplasty carries a built-in ceiling set by harvest-site capacity. Because plugs come from the same low-load donor zones described earlier in this article, the total graft area available from a single knee is finite, which limits the technique's use as defect size grows.

Once a lesion reaches approximately 3 cm² or larger, neither mosaicplasty nor microfracture is the preferred choice. The SUMMIT trial demonstrated that MACI produced superior KOOS pain and function scores at both two and five years compared with microfracture for defects of this size. At this threshold, osteochondral allograft or cell-based approaches such as MACI tend to become the more appropriate options — a decision that warrants its own separate consideration.

Recovery after mosaicplasty and microfracture

Recovery from both procedures follows a broadly similar early course, though the protocols diverge in one clinically meaningful way.

For tibiofemoral lesions, protected weight-bearing of six to eight weeks is standard after either operation. During this period, the repair tissue — whether newly forming fibrocartilage or integrating osteochondral plugs — needs to be shielded from full axial load to allow consolidation.

Where the protocols differ most clearly is in the role of continuous passive motion (CPM). After microfracture, CPM is considered important for fibrocartilage maturation: gentle, repeated joint movement is thought to support nutrient delivery and the mechanical organisation of the repair clot during the weeks when weight-bearing is restricted. Mosaicplasty does not carry the same CPM dependency, because the transplanted plugs bring structurally intact cartilage rather than a clot that must differentiate under the right conditions. Structured physiotherapy remains essential after mosaicplasty — to restore quadriceps strength, range of motion, and neuromuscular control — but the protocol is less tightly bound to passive motion devices.

In the short term, return to daily activity and low-impact exercise follows a similar trajectory for both techniques. The more meaningful divergence appears over years rather than months: the ten-year evidence, anchored in the Gudas et al. RCT, suggests that patients who underwent mosaicplasty maintain higher functional levels at long-term follow-up than those treated with microfracture — a difference that is less about the early rehabilitation phase and more about the durability of the underlying repair tissue described in earlier sections.

Long-term joint health and when to seek assessment

The strongest long-term argument for choosing a durable cartilage repair procedure is not about surgical scores — it is about osteoarthritis. Sanders et al. (Am J Sports Med, 2017) tracked patients at a mean 16-year follow-up after osteochondritis dissecans treatment and found substantially higher rates of knee OA in those whose lesions had been managed by fragment excision rather than surgical restoration. Though that study did not compare repair techniques head to head, its underlying message extends directly to the microfracture versus mosaicplasty question: a fibrocartilage repair that degrades progressively may offer less protection against joint-space narrowing than one built on durable hyaline cartilage.

For any patient with a known focal cartilage defect who has not had it formally assessed, physiotherapy alone is unlikely to address the structural problem. Consultant-led evaluation — including dedicated MRI to characterise defect size, depth, and the condition of the surrounding subchondral bone — is the necessary first step before any surgical decision can be made responsibly.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. The ten-year evidence reviewed in this article points consistently in one direction: the quality of the repair tissue placed today shapes what the joint looks like a decade, and quite possibly two decades, from now.

1. [1] Microfracture Surgery — Wikipedia. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994